Details for Patent: 10,603,290

« Back to Dashboard

Which drugs does patent 10,603,290 protect, and when does it expire?

Patent 10,603,290 protects FINTEPLA and is included in one NDA.

Protection for FINTEPLA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-four patent family members in fifteen countries.

Summary for Patent: 10,603,290

Title:	Formulation for inhibiting formation of 5-HT2B agonists and methods of using same
Abstract:	Drug combinations and their use are disclosed. A first drug is administered in combination with a second drug. The first drug such as fenfluramine is characterized by the formation of a metabolite including 5-HT2B agonists such as norfenfluramine with known adverse side effects. The second drug is in the form of a CYP inhibitor such as cannabidiol which modulates the formation of metabolite down thereby making the first drug safer.
Inventor(s):	Stephen J. Farr, Brooks Boyd
Assignee:	Zogenix International Ltd
Application Number:	US16/193,812
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,603,290
Patent Claim Types: see list of patent claims	Use; Formulation;

Drugs Protected by US Patent 10,603,290

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Ucb Inc	FINTEPLA	fenfluramine hydrochloride	SOLUTION;ORAL	212102-001	Jun 25, 2020		RX	Yes	Yes	10,603,290*PED				Y

International Family Members for US Patent 10,603,290

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2017315273
Australia	2021204250
Australia	2022279469
Canada	3032996
China	109689103
China	120241681
European Patent Office	3518975